Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 12/20 | 0.62 |
| ▸ | PREP | P48147 | 1/20 | 0.60 |
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.57 |
| ▸ | DPP9 | Q86TI2 | 3/20 | 0.57 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1239549 | 1.00 | DPP4 (0.62) | DPP4PREPDPP8DPP9CHRM2 | |
| SCHEMBL11469779 | 0.98 | DPP4 (0.60) | DPP4PREPDPP8DPP9CHRM2 | |
| Hydrochloric Acid SCHEMBL5964647 | 0.98 | DPP4 (0.60) | DPP4PREPDPP8DPP9CHRM2 | |
| Hydrochloric Acid SCHEMBL5964641 | 0.98 | DPP4 (0.60) | DPP4PREPDPP8DPP9CHRM2 | |
| Hydrochloric Acid SCHEMBL27511587 | 0.98 | DPP4 (0.60) | DPP4PREPDPP8DPP9CHRM2 | |
| Ammonia Solution, Strong SCHEMBL27597606 | 0.98 | DPP4 (0.60) | DPP4PREPDPP8DPP9CHRM2 | |
| SCHEMBL11820231 | 0.94 | CHRM2 (0.57) | DPP4PREPDPP8DPP9CHRM2 | |
| SCHEMBL11451025 | 0.92 | CHRM2 (0.55) | DPP4PREPDPP8DPP9CHRM2 | |
| SCHEMBL1819999 | 0.82 | CHRM2 (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL2269972 | 0.82 | CHRM2 (0.56) | CHRM2CHRM4CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103508931-A | Hexahydropentaleno derivatives, preparation methods and applications in medicine thereof | GUANGDONG HEC PHARMACEUTICAL | 2014-01-15 | — | — | CN | claimed |
| EP-1953162-B9 | Xanthin derivatives, their production and utilisation as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-10-31 | — | — | EP | claimed |
| EP-1953162-B1 | Xanthin derivatives, their production and utilisation as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2012-06-20 | — | — | EP | claimed |
| EP-2079469-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR PREVENTING, DELAYING OR REDUCING THE OCCURANCE OF EDEMA | Novartis AG (CH) | 2009-07-22 | — | — | EP | claimed |
| EP-1928499-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | Novartis AG (CH) | 2008-06-11 | — | — | EP | claimed |
| WO-2008057337-A2 | USE OF DIPEPTIDYL PEPTIDASE IV INHIBITORS FOR PREVENTING, DELAYING OR REDUCING THE OCCURANCE OF EDEMA | NOVARTIS AG (CH) | 2008-05-15 | — | — | WO | claimed |
| WO-2007035665-A1 | USE OF A DPP-IV INHIBITOR TO REDUCE HYPOGLYCEMIC EVENTS | NOVARTIS AG (CH) | 2007-03-29 | — | — | WO | claimed |
| EP-1732550-A2 | DPP-IV INHIBITORS FOR TREATING NEURODEGENERATION AND COGNITIVE DISORDERS | Novartis AG (CH) | 2006-12-20 | — | — | EP | claimed |
| WO-2005079795-A2 | DPP-IV INHIBITORS FOR TREATING NEURODEGENERATION AND COGNITIVE DISORDERS | NOVARTIS AG (CH) | 2005-09-01 | — | — | WO | claimed |
| WO-2021116897-A1 | PROCESS FOR THE PREPARATION OF VILDAGLIPTIN | OPTIMUS DRUGS (P) LTD (IN) | 2021-06-17 | — | — | WO | disclosed |
| WO-2017027768-A1 | COMPOSITIONS AND METHODS FOR TREATING TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2017-02-16 | — | — | WO | disclosed |
| CN-103508931-A | Hexahydropentaleno derivatives, preparation methods and applications in medicine thereof | GUANGDONG HEC PHARMACEUTICAL | 2014-01-15 | — | — | CN | disclosed |
| EP-1910385-B1 | BENZOTHIAZOLES AND THIAZOLOPYRIDINES AS SIRTUIN MODULATORS | SIRTRIS PHARMACEUTICALS INC (US) | 2013-07-24 | — | — | EP | disclosed |
| CN-101037409-B | Process for the preparation of n-substituted 2-cyanopyrrolidines | NOVARTIS AG | 2013-03-27 | — | — | CN | disclosed |
| EP-1487807-A2 | NEW COMPOUNDS | Sanofi-Aventis (FR) | 2004-12-22 | — | — | EP | disclosed |
| EP-1441719-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-04 | — | — | EP | disclosed |
| WO-2004052362-A1 | COMBINATION OF AN DPP-IV INHIBITOR AND A PPAR-ALPHA COMPOUND | NOVARTIS AG (CH) | 2004-06-24 | — | — | WO | disclosed |
| CN-1468216-A | Nitrogenous five-membered ring compound | ������ҩ��ʽ���� | 2004-01-14 | — | — | CN | disclosed |
| WO-2003074500-A2 | N-AMINOACETYL-PYRROLIDINE-2-CARBONITRILES AND THEIR USE AS DDP-IV INHIBITORS | SANOFI-AVENTIS (FR) | 2003-09-12 | — | — | WO | disclosed |
| WO-2003037327-A1 | N-SUBSTITUTED PYRROLIDIN DERIVATIVES AS DIPEPTIDYL PEPTIDASE IV INHIBITORS | F. HOFFMANN-LA-ROCHE AG (CH) | 2003-05-08 | — | — | WO | disclosed |